[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
Putin can ’t count on his friends in Italy anymore
When Italian Prime Minister Giorgia Meloni walks into the Oval Office on Thursday, her transformation will be complete. Gone is the ghoulish caricature of an extremist monster, sympathetic to Moscow, whose party was descended from fascists, and in her place stands a pragmatic conservative willing…#italian #giorgiameloni #ovaloffice #moscow #ukraine #g7 #meloni #europeanunions #democrat #antoniotajani (Source: Reuters: Health)
Source: Reuters: Health - July 27, 2023 Category: Consumer Health News Source Type: news
Existential spectrum of suffering: concepts and moral valuations for assessing intensity and tolerability - Duffee C.
This paper has two aims. The first is to defend a recent critique of the leading medical theory of suffering, which alleges too narrow a focus on violent experiences of suffering. Although sympathetic to this critique, I claim that it lacks a counterexampl... (Source: SafetyLit)
Source: SafetyLit - July 24, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Media News - July 21, 2023 Category: Pharmaceuticals Source Type: news
CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Investor Update - July 21, 2023 Category: Pharmaceuticals Source Type: news
Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs
The company last month promised cost reductions after its drug pamrevlumab failed two late-stage clinical trials, in the lung-scarring disease idiopathic pulmonary fibrosis and Duchenne muscular dystrophy. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 19, 2023 Category: Biotechnology Authors: Ron Leuty Source Type: news
Science Saturday: Mayo Clinic discovery leads to diagnoses of 9 people with rare form of muscular dystrophy
Nine people around the world who have been living with unexplained, muscular dystrophy-like symptoms may now have an answer for what is causing the progressive muscle weakness in their body ’s mid-section, arms and legs. In a new discovery, a collaborative team of scientists led by researchers at Mayo Clinic ’s Center for Individualized Medicine has pinpointed alterations in a single gene deep inside these people's genetic blueprint as the root cause of their ultra-rare disorder, known as limb-girdle muscular… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 15, 2023 Category: Databases & Libraries Source Type: news
Russia has launched its own version of Wikipedia, called Ruwiki, which is notably more sympathetic to Putin
A composite image showing a headshot of President Vladimir Putin on June 24, 2023, and the Ruwiki logo. Sputnik/Gavriil Grigorov/Kremlin via Reuters / Ruwiki / Insider A Kremlin-compliant version of Wikipedia, Ruwiki, has launched in Russia. Its founder, a former longtime editor at Russian…#vladimirputin #ruwiki #kremlin #wikipedia #russianwikipedia #russian #ukrainewar #prigozhin #vladimirmedeyko #telegraph (Source: Reuters: Health)
Source: Reuters: Health - July 13, 2023 Category: Consumer Health News Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Investor Update - July 13, 2023 Category: Pharmaceuticals Source Type: news
First Gene Therapy for Deadly Form of Muscular Dystrophy Gets FDA Approval for Young Kids
The FDA OK'd the treatment only for children ages 4 and 5, based on study results showing the therapy helped produce a protein needed for muscle growth, which is missing in boys with the condition. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - July 6, 2023 Category: American Health Source Type: news
Muscular dystrophy: Child racks up 1,200 miles a month for treatment
Muscular dystrophy patient Elliot, five, makes the journey from Newport to Newcastle twice a month. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 4, 2023 Category: Consumer Health News Source Type: news
Four-year follow up data for Roche ’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk
Data from ongoing FIREFISH study confirm long-term efficacy and safety profile ofEvrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the ability to swallow- without treatment they would have required feeding support and majority would have died within 2 yearsEvrysdi is now approved in 99 countries with more than 8,500 patients treated globallyBasel, 30 June 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new long-term data for Evrysdi ® (risdiplam) from the open-label extension (n=50) of the pivotal FIREFISH study, reinforcing its sustained efficacy an...
Source: Roche Investor Update - June 30, 2023 Category: Pharmaceuticals Source Type: news
Four-year follow up data for Roche ’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk
Data from ongoing FIREFISH study confirm long-term efficacy and safety profile ofEvrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the ability to swallow- without treatment they would have required feeding support and majority would have died within 2 yearsEvrysdi is now approved in 99 countries with more than 8,500 patients treated globallyBasel, 30 June 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new long-term data for Evrysdi ® (risdiplam) from the open-label extension (n=50) of the pivotal FIREFISH study, reinforcing its sustained efficacy an...
Source: Roche Media News - June 30, 2023 Category: Pharmaceuticals Source Type: news
Monthly News Roundup - June 2023
Elevidys is First Gene Therapy Cleared to Treat Duchenne Muscular Dystrophy
In June, the FDA granted accelerated approval of Elevidys (delandistrogene moxeparvovec-rokl) from Sarepta Therapeutics, Inc. Elevidys is an adeno-associated virus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2023 Category: Pharmaceuticals Source Type: news
